Activist investors are reshaping the corporate landscape—are you ready to lead the change or be led by it? In today's rapidly evolving business environment, companies like Pfizer are facing unprecedented scrutiny from activist investors. As a digitally savvy board director with over 25 years of experience, I've seen firsthand how proactive governance can transform challenges into opportunities. Here's how boards can stay ahead of the curve: 1. Adopt an Activist Mindset: Don't wait for activists to highlight your vulnerabilities. Proactively identify and address potential weaknesses in strategy, performance, and governance. This isn't just about defense; it's about steering the ship with foresight and agility. 2. Self-Assessment is Key: Regularly evaluate your performance across critical areas—from shareholder returns to ESG performance. This holistic approach ensures you're not just meeting expectations but exceeding them. 3. Focus on Margins, Not Just Growth: In the quest for revenue, don't lose sight of profitability. Prioritizing margin improvement can offer a more sustainable path to value creation. 4. Embrace Diverse Perspectives: Be open to external insights and ready to make tough decisions early. Delaying action only amplifies risks. 5. Communicate Clearly: In times of crisis, a measured response can mitigate criticism. Transparency and strong communication with institutional investors can prevent them from siding with activists. 6. Engage Constructively: Consider private dialogues with activists. Constructive engagement can lead to mutually beneficial outcomes without the public spectacle. 7. Prioritize ESG: Environmental and social demands are no longer peripheral—they're central to activist campaigns. Address these proactively to align with evolving stakeholder expectations. 8. Strategic Flexibility: Be prepared to evaluate and execute strategic changes, including M&A activities or divestitures, to unlock shareholder value. As leaders, it's our responsibility to not only navigate these challenges but to turn them into catalysts for growth and innovation. Let's champion a future where corporate purpose and profitability go hand in hand. What steps are you taking to prepare your board for the future? Share your thoughts and let's drive this conversation forward. #CEO #KSgems #BoardOversight #CFO #CIO #CTO #CISO #Leadership #Innovation #Governance #Activist #BoardDirector Kara Reinhardt Lauren Thomas James Callan Andrew Barker Jake Perez https://lnkd.in/eF5H4dpR
Khwaja Shaik的动态
最相关的动态
-
Pfizer's recent upward revision of its 2024 revenue forecast to $61-$64 billion has caught the market's attention, leading to a 1.8% stock increase. While strong demand for cancer and COVID-19 drugs fuels this optimism, an ominous shadow looms—activist investor Starboard Value's $1 billion stake. They argue that Pfizer’s management has mismanaged resources, costing shareholders about $20 billion. This tension presents a crucial opportunity for Pfizer: will they embrace the challenge and adapt, or risk stagnation amid external pressure? The stakes couldn’t be higher, as Starboard’s call for accountability could reshape Pfizer’s strategic direction. As we witness this corporate drama unfold, it serves as a stark reminder that financial forecasts, while essential, must be backed by sound governance and innovative strategy. Pfizer's path forward could set a precedent for other pharma giants navigating the post-pandemic landscape. What are your thoughts on this evolving scenario?
Pfizer Boosts 2024 Forecast Amid Rising Pressure from Activist Investor Over $20B 'Lost Value'
ctol.digital
要查看或添加评论,请登录
-
Partners Steve Sapletal and Kristin Pothier continued the innovation theme at JPM with back to back panels on KPMG's End to End M&A. Joined by colleagues from Baxter (Chrissy Finkel, CMA and Soumya "SDR" Dutta Roy, MBA, PMP), Lilly (Steve Walker), Merck KGaA (Karen Madden), Morgan Stanley (David Kitterick), Ascidian (Daniel Rosan), and BeiGene (Scott Carter), zthey debated the balance of innovation and realization in life sciences today, and the most critical global methods to put in place, from inception of a deal, to the diligence required, to the integration of the asset, to the transformation of the resulting company. Read our investment report and look for our replays! https://lnkd.in/e2XGAiYQ #KPMGHCLS #KPMGTransactions #JPMHC25
要查看或添加评论,请登录
-
-
The #cannabisindustry has seen it all—booms, busts, and everything in between. While past years have brought challenges, today’s landscape offers unprecedented opportunities for those who know where to look. With strategic deal structures, attractive valuations, and standout leadership teams, the current market is primed for savvy investors ready to make bold moves. Check out the break down. #cannabisinvesting #markettrends #investment
Why 2025 could be a banner year for cannabis investors
https://mjbizdaily.com
要查看或添加评论,请登录
-
Only put off until tomorrow what you are willing to die having left undone. Starboard Alleges Coercion by Pfizer: A Blow to Investor Confidence in Bourla's Backing In a recent move that has shaken the investor community, Starboard issued a letter to Pfizer's board, accusing the company of attempting to coerce Read and D'Amelio into backing Bourla. This allegation has sparked concerns about the level of transparency and integrity within Pfizer's management. The development comes as a blow to those who were hoping for continued support from former executives, as their withdrawal could signal a lack of confidence in Bourla's leadership. The fallout from this incident has led to a decline in Pfizer's stock price. Investors are advised to closely monitor the situation as it unfolds. It is crucial to stay informed and make well-informed investment decisions based on the latest developments. Taking action now can help avoid the Fear of Missing Out (FOMO) and safeguard your investments. For those looking to maximize their investment potential, exploring opportunities within Health Savings Accounts (HSAs) may be a prudent strategy. The combination of healthcare and investing offers a unique avenue for growth while prioritizing one's well-being and that of their family. Don't miss out on the chance to grow your HSA with smart investment choices in the healthcare sector. #hsa #investing #healthcare #health #family #wellness ??????????
Pfizer Stock Falls As Former Execs Pull Back From Starboard’s Activist Campaign: Retail Still Sees Hope
stocktwits.com
要查看或添加评论,请登录
-
A recent article published by EY highlights the challenges facing the biopharma industry, emphasizing the importance of ecosystems in overcoming the innovation gap. Companies must expand their alliances, mergers, and partnerships to drive efficiency and foster innovation in the face of patent expirations and declining pipeline replenishment rates. Key Takeaways: - Biopharma risks $226 billion in global sales by 2026 due to patent expirations. - High-performing ecosystems offer faster and less risky ways to replenish pipelines. - Ecosystems complement M&A, providing agility in pipeline development. - The replenishment rate is projected to drop by over 50%, necessitating innovation strategies. - Early alliances, especially with Phase II assets, can enhance R&D returns. For more insights, check out my article series on LinkedIn and Forbes Business Council. #technology #innovation #future #digitalmarketing #influencer #topvoice #business #pharma #healthtech #healthcare #biotech #lifesciences #author #editor Image: EY
要查看或添加评论,请登录
-
-
In today's Seaspray Financial Services Ltd data insight we continue our focus on earnings season, with some of the largest companies in the world reporting their Q3 earnings this week. This included five of the Magnificent 7, as well as major pharmaceutical and financial companies. #corporateearnings #sp500 #pharma #financial #mag7 #equities #longterminvesting https://lnkd.in/eaQGPTB2
Taking Stock - Q3 Earnings Season - Week 3.
https://seasprayfinancialservices.ie
要查看或添加评论,请登录
-
Every action we take is fueled by our commitment to creating a positive impact and driving meaningful change. Our Environmental, Social, and Governance (ESG) initiatives are at the heart of who we are, and our entire team is dedicated to making them a reality. Discover more about our ESG journey here > https://lnkd.in/ekD3uiYj #ESG #CSR #Environment
Driving Positive Impact in Drug Development: tranScrip's Commitment to ESG - tranScrip
transcrip-group.com
要查看或添加评论,请登录
-
#Pharma firms pressed to relax #patents for #developingcountries, as #investors emphasise the need for companies to increase voluntary licensing of #medicines after new benchmark report revealed slowdown. Comments from Jayasree Iyer (Access to Medicine Foundation), Meg Jones-Monteiro (Interfaith Center on Corporate Responsibility (ICCR)), and Frank Wagemans (Achmea Investment Management). Read more of Jack Grogan-Fenn's news piece here: https://lnkd.in/eAaM2s5U
Pharma Firms Pressed to Relax Patents for Developing Countries - ESG Investor
https://www.esginvestor.net
要查看或添加评论,请登录
更多文章
-
Khwaja's Take: DeepSeek, TikTok ban, $500 B Stargate, Agentic AI, Cyber Risk and much more!!
Khwaja Shaik 1 个月 -
Khwaja's Take: Blackrock's Pivot, Tesla's FSD, Agentic AI, Simplification, Antitrust, Starboard Activism, Talent Reset, Quantum Threat, and much more!
Khwaja Shaik 1 个月 -
Khwaja's Take: Intel's Failures, Jet Blue Fines, Apple Settlement, Treasury Breach, and much more!!
Khwaja Shaik 1 个月